Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference
Prelude Therapeutics, a clinical-stage precision oncology company (Nasdaq: PRLD), has announced that CEO Kris Vaddi, PhD, will present at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 5:00 p.m. ET. The presentation will be available via live webcast on the Company’s investor website, with a replay accessible later.
Prelude is developing innovative oral drug candidates for critical cancer pathways, including PRT543 and PRT811, both in Phase 1 trials targeting advanced tumors and glioblastoma. Their pipeline also includes PRT1419, a promising MCL1 inhibitor.
- CEO Kris Vaddi will present at a significant industry conference, potentially raising investor interest.
- Prelude's lead product candidates are in active clinical trials, indicating progress in cancer treatment development.
- The pipeline includes several innovative drug candidates, suggesting robust future growth potential.
- None.
WILMINGTON, Del., May 05, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12 at 5:00 p.m. ET.
A live webcast of the presentation chat can be accessed under “Events & Presentations” in the Investor Section of the Company’s website, https://investors.preludetx.com/news-and-events/events-and-presentations, where a replay of the presentation will also be available for a limited time.
About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.
Contact
Investors: Melissa Forst
Media: Deborah Elson
Argot Partners
212.600.1902
prelude@argotpartners.com
FAQ
What is Prelude Therapeutics' stock symbol?
When will the CEO of Prelude Therapeutics present at the BofA Securities Virtual Health Care Conference?
How can I access the webcast of Prelude Therapeutics' presentation?
What is the current status of Prelude Therapeutics' clinical candidates?
What types of cancer is Prelude Therapeutics targeting?
